SALT LAKE CITY and AUSTIN, Texas, June 1, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has completed the previously announced acquisition of Rules-Based Medicine (RBM) for approximately $80 million in cash.
SALT LAKE CITY and AUSTIN, Texas, June 1, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has completed the previously announced acquisition of Rules-Based Medicine (RBM) for approximately $80 million in cash.
